No Data
Hong Kong-listed innovative drug Concept stocks surged in the afternoon! Driven by bullish policies and business development expectations, institutions say the sector's current valuation remains attractive.
It is worth mentioning that, according to data from Zhongyou Securities, the total amount of License-out for Chinese innovative drugs in the first half of this year has approached 66 billion USD, surpassing the total amount of BD transactions for the entirety of 2024, and MNC's interest in Chinese innovative drug Assets is expected to continue.
The Hong Kong stock market is warming up with innovative drugs continuing to be strong. As the mid-term report window approaches, what are the expectations of the Institutions?
① The Hong Kong stock market is warming up and innovative drugs continue to strengthen; which stocks are leading the rise in the short term? ② As the mid-term reporting window approaches, how do Institutions view the Sector's trends in July?
[Brokerage Focus] BOCOM INTL: The current valuation of the Hong Kong stock market's innovative drug Sector remains attractive.
Jinwu Financial News | BOCOM INTL believes that the valuation of the current Hong Kong stock innovative drug sector remains attractive: 1) The forward P/S ratio of leading innovative pharmaceutical companies is basically in line with the historical average since the bear market, though slightly higher than comparable companies in the US stock market, but the revenue growth expectations are also far superior to the latter; 2) Currently, the leading Hong Kong stocks have a P/S ratio of about 3 times at the peak of their revenue, with some companies only around 2 times, lower than the average 4 times in the US stock market; 3) In the first half of 2025, domestic investors continued to increase their positions through the Stock Connect, but foreign institutions' Hold Positions in innovative drugs are at a low point. Regarding the evolution direction of innovative drugs going overseas, the institution observes the following trends: 1) The industry has further derived new types such as NewCo.
The concept of innovative drugs continues to rise, with multiple policies introduced to support the high-quality development of innovative drugs, and the commercial insurance innovative drug catalog is expected to be implemented.
On the news front, on July 11, the National Medical Insurance Administration officially initiated the adjustment application for the 2025 national basic medical insurance, maternity insurance, and work injury insurance drug catalog, as well as the newly established commercial health insurance innovative drug catalog.
Express News | A new directory of innovative commercial insurance drugs has been added, with the adjustment of the medical insurance directory officially starting in 2025.
U.S. Market Close: S&P and Nasdaq Continue to Reach New Highs, Cryptocurrency Concept and Rare Earth Stocks Surge
① NVIDIA's Market Cap first closed above 4 trillion; ② Coinbase and Robinhood rose over 4%; ③ Rare earth stock MP Materials increased by over 50%; ④ Popular Chinese stocks overall rose, ZTO Express increased by 9%.